Trastuzumab Deruxtecan Is Active in HER2-Mutant NSCLC

HER2 mutations drive roughly 3% of nonsquamous non–small-cell lung cancers (NSCLC) and are often seen in patients who are slightly younger, female, and never-smokers. This subtype also carries a poor prognosis and an increased incidence of brain metastasis. These patients typically receive standard chemotherapy and/or immunotherapy.

Trastuzumab deruxtecan is a HER2 antibody–drug conjugate. In the DESTINY-Lung01 trial, investigators assessed the efficacy and safety of trastuzumab deruxtecan in 91 patients with HER2-mutant NSCLC who had relapsed on or were refractory to standard therapy. Centrally confirmed objective response occurred in 55% of the patients (95% CI, 44–65). A disease control rate of 92.3% was observed, with a decrease in tumor…